Table 3.
Week | Treatment | Viable | Non-Viable | ||
---|---|---|---|---|---|
Zygote | DE | L1 | |||
0 | Control | 142 ± 10 (91%) | 9 ± 4 (6%) | 5 ± 1 (3%) | 2 ± 1 |
CR | 142 ± 10 (91%) | 9 ± 4 (6%) | 5 ± 1 (3%) | 2 ± 1 | |
TA | 142 ± 10 (91%) | 9 ± 4 (6%) | 5 ± 1 (3%) | 1 ± 1 | |
1 | Control | 9 ± 2 (6%) | 27 ± 6 (17%) | 121 ± 17 (77%) | 11 ± 6 |
CR | 38 ± 10 (26%) | 43 ± 11 (29%) | 66 ± 27 (45%) | 18 ± 9 | |
TA | 60 ± 15 (40%) | 50 ± 10 (34%) | 39 ± 9 (26%) | 17 ± 7 | |
2 | Control | 4 ± 1 (3%) | 11 ± 2 (7%) | 136 ± 8 (90%) | 17 ± 5 |
CR | 23 ± 4 (20%) | 29 ± 6 (24%) | 67 ± 13 (56%) | 48 ± 8 | |
TA | 28 ± 2 (26) | 25 ± 8 (23%) | 56 ± 6 (51%) | 46 ± 7 | |
3 | Control | 24 ± 9 | |||
CR | 13 ± 3 (13%) | 16 ± 8 (16%) | 70 ± 5 (71%) | 52 ± 8 | |
TA | 17 ± 3 (17%) | 26 ± 7 (26%) | 58 ± 10 (57%) | 60 ± 5 |